Abstract: An electrodeless dichromatic flickering bulb includes: a built-in chip, a first light-emitting-diode element and a second light-emitting-diode element; the built-in chip includes a first input terminal, a second input terminal, a first output terminal and a second output terminal, the first input terminal is electrically connected to the first output terminal, and the second input terminal is electrically connected to the second output terminal; an anode of the first light-emitting-diode element is electrically connected to the first output terminal, a cathode of the first light-emitting-diode element is electrically connected to the second input terminal, an anode of the second light-emitting-diode element is electrically connected to the second output terminal, and a cathode of the second light-emitting-diode element is electrically connected to the first input terminal.

Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Abstract: The present invention provides a supported metal catalyst with synergistic sites, a preparation method therefor and an application thereof. The preparation method of this catalyst is to utilize the unsaturated cubane-like structure, M cation with catalytic activity is introduced into the cluster core unit. By using the vertex vacancy as the capturing center, and adjusting the impregnation temperature to maximize the loading of the cluster precursor, as well as depending on the electrostatic adsorption of the support and the confinement of the cluster structural unit, the number of S vacancies and the distance between S vacancies and Miso sites are effectively controlled through liquid phase reduction and atmosphere treatment at room temperature to obtain supported X3MSx/Al2O3 catalyst with Miso-Vs synergistic sites.

Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Abstract: Cuy/MMgOx interfacial catalyst for selective alkyne hydrogenation and its preparation method are disclosed. The preparation method of the catalyst includes: the mixture of salt and alkali solution is nucleated momentarily by nucleation/crystallization isolation method, preparing the composite metal hydroxide CuyMMg4-LDHs as precursor, which has typical hexagonal morphology of the double hydroxide; the precursor is topologically transformed by heat treatment to produce unsaturated oxide; the catalyst with Cuy-MMgOx interface structure is prepared by separating and electronically modifying Cu particles. By adjusting the ratio of Cu2+/M3+ in LDHs, the electronic and geometric structure of Cuy-MMgOx interface can be flexibly controlled, thus enhancing the reaction activity, product selectivity and stability. The catalyst can be used in the selective hydrogenation of various alkynes in the fields of petrochemical and fine chemical industry, with the outstanding catalytic activity and C?C double bond selectivity.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: The present invention discloses a catalyst for in-situ CO2 capture and coupling reduction with biomass oxidation, a preparation method therefor and an application thereof. The catalyst is applied to the coupling reaction of photocatalytic CO2 reduction and biomass oxidation. The preparation of the catalyst is to synthesize layered double hydroxides (LDHs) containing CO32? between layers by using coprecipitation method, hydrothermal method, sol-gel method and the like, wherein the chemical formula is [M1-x2+Mx3+(OH)2]x+(An?)x/n·mH2O, which has a thickness of 20-30 nm and an average particle diameter of 60-90 nm. Then metal ion vacancy defects are produced on LDHs laminate by using a NaOH/KOH selective etching to obtain the corresponding catalyst.

Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with viral infections, such as those due to coronaviruses that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries often associated with these infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/AP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof, The present invention also provides devices for administering the compositions.

Abstract: The disclosure includes methods of preventing, ameliorating, and/or treating ischemia-reperfusion injury (IRI), including but not limited to post brain stroke, using a MAP3K2/MAP3K3 inhibitor. In another aspect, the present disclosure relates to methods of preventing, ameliorating, and/or treating a lung injury related to a coronavirus infection, acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) using a MAP3K2/MAP3K3 inhibitor. The disclosure further comprises compositions, and kits comprising compositions useful within the disclosure.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.

Abstract: Cuy/MMgOx interfacial catalyst for selective alkyne hydrogenation and its preparation method are disclosed. The preparation method of the catalyst includes: the mixture of salt and alkali solution is nucleated momentarily by nucleation/crystallization isolation method, preparing the composite metal hydroxide CuyMMg4-LDHs as precursor, which has typical hexagonal morphology of the double hydroxide; the precursor is topologically transformed by heat treatment to produce unsaturated oxide; the catalyst with Cuy-MMgOx interface structure is prepared by separating and electronically modifying Cu particles. By adjusting the ratio of Cu2+/M3+ in LDHs, the electronic and geometric structure of Cuy-MMgOx interface can be flexibly controlled, thus enhancing the reaction activity, product selectivity and stability. The catalyst can be used in the selective hydrogenation of various alkynes in the fields of petrochemical and fine chemical industry, with the outstanding catalytic activity and C?C double bond selectivity.

Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.

Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Abstract: A connector includes a first connecting assembly and a second connecting assembly, wherein the first connecting assembly and the second connecting assembly are fitted with each other. The first connecting assembly includes a first inner core and at least two first electric wires, and each of the first electric wires is electrically connected in a first end portion of the first inner core. The second connection assembly includes a second inner core and at least two second electric wires, and each of the second electric wires is electrically connected in a first end portion of the second inner core. A second end portion of the second inner core is provided with a connecting portion, and the connecting portion is inserted in a second end portion of the first inner core, so that the first electric wire is in an electrical communication with the second electric wire.